Troll Busters LLC v. Roche Diagnostics GmbH et al.

Case overview

This is not a patent infringement suit. Despite the "Patent Infringement / 28 U.S.C. § 1338" cause-of-action code on the docket, Troll Busters, LLC v. Roche Diagnostics GmbH, No. 3:11-cv-00056-IEG-WVG (S.D. Cal., filed Jan. 10, 2011) was a qui tam false-marking action under 35 U.S.C. § 292 — a relator suit brought "on its own behalf and on behalf of the United States," seeking the statutory penalty of "not more than $500 for each instance" of violation, half payable to the government. See Order of Aug. 31, 2011 (Doc. 162) at 3–4, https://cases.justia.com/federal/district-courts/california/casdce/3:2011cv00056/[341819/162](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=341819-0162)/0.pdf. The plaintiff, Troll Busters LLC, was not an operating company, competitor, university, or technology developer. It publicly marketed itself as a patent "assassin" that "invalidates patents … being asserted by patent trolls," and commentators promptly labeled it (and similar relators) a "marking troll" — the irony being that a non-competitor qui tam relator is structurally the same kind of entity it claimed to oppose. See False Patent Marking blog, "The Troll Busters® Irony: from 'buster' to 'troll'" (Jan. 18, 2011), http://falsepatentmarking.blogspot.com/2011/01/troll-busters-irony-from-buster-to.html, citing Forest Group, Inc. v. Bon Tool Co., 590 F.3d 1295, 1303 (Fed. Cir. 2009). Docket-aggregator data lists Karl A. Rupp (San Diego) as plaintiff's counsel; I could not independently verify the full counsel roster from a primary source. On the defense side, the four principal defendants named in the case metadata are the Roche entities — Roche Diagnostics GmbH (Basel, Switzerland parent), Roche Molecular Systems (Pleasanton, CA), and Roche Diagnostics Corp. (Indianapolis) — plus Life Technologies Corp., the Invitrogen/Applied Biosystems combination headquartered in Carlsbad, CA. Caveat on party scope: the Justia and UniCourt dockets show a substantially broader defendant list than the four in the case metadata, including Roche Applied Sciences, Eurogentec North America, Clontech Laboratories, Integrated DNA Technologies, Qiagen NV, Thermo Fisher Scientific, Quanta Biosciences, Gene Link, GenScript USA, EMD Chemicals, TriLink BioTechnologies, and Cepheid (Justia docket, https://dockets.justia.com/docket/california/casdce/3:2011cv00056/[341819](/patent/341819)). The UniCourt entry also lists the United States as an "Intervenor Defendant" with DOJ counsel (Thomas C. Stahl), consistent with DOJ's practice of intervening to defend § 292(b)'s constitutionality — a point I could not confirm from a primary filing.

The accused "product" is a licensing and marking program, not an infringing device. The First Amended Complaint (Doc. 84, filed Apr. 8, 2011) alleged that defendants marked — or required their licensees to mark — Taq DNA polymerases, PCR reagents and kits, real-time PCR probes/master mixes, and related instrumentation (e.g., Roche's FastStart Taq DNA Polymerase and LightCycler® 480 Probes Master, Eurogentec's Diamond Taq®) with patent numbers that had already expired, and that defendants' websites and product literature continued to tell customers a license was needed to practice PCR. See FAC analysis, https://ai-lab.exparte.com/case/dct/casd/3:11-cv-00056/doc/analysis/84. The theory was that Roche and Life, as licensors (and Life as alleged Roche "agent"), propagated the expired numbers through licensees who were contractually obligated to mark, thereby deterring competitors and suppressing post-expiration price competition — the core competitive harm § 292 targets. The FAC tabulated well over 100 Roche products across multi-page tables and pleaded 22 expired PCR/molecular-biology patents, not just the single patent in the case metadata; among them were U.S. 4,683,195 and 4,683,202 (the original Cetus PCR process patents — exponential amplification using two primers and a polymerase), U.S. 4,965,188 (PCR using a thermostable enzyme, i.e., automating PCR by eliminating enzyme replenishment after each denaturation step), U.S. 5,219,727 (PCR quantitation using an internal standard), and the patent the metadata isolates, U.S. 4,889,818, "Purified Thermostable Enzyme" — the Taq DNA polymerase patent, with just three claims to purified Thermus aquaticus DNA polymerase of 86,000–90,000 daltons, its native isolate, and its recombinant form. The '818 patent issued Dec. 26, 1989 to Cetus, was assigned to Hoffmann-La Roche and Roche Molecular Systems in December 1991, and (measured from its issue date under the pre-URAA 17-year term) expired in December 2006 — squarely within the FAC's allegation that several of the patents expired in 2005–2006. Notably, the '818 claims had earlier been held unenforceable for inequitable conduct in Hoffmann-La Roche v. Promega (N.D. Cal. 1999), aff'd, 323 F.3d 1354 (Fed. Cir. 2003) — a wrinkle that made marking with the '818 number even harder to defend on a "we reasonably believed we had patent rights" theory.

Procedural posture and why it matters. The case landed in the Southern District of California's San Diego division before Chief Judge Irma E. Gonzalez (a Clinton appointee), with Magistrate Judge William V. Gallo — a venue that mattered because Carlsbad-based Life Technologies and a dense cluster of PCR reagent suppliers sat in the district, and because the plaintiff was California-based. Roughly eleven defendant groups moved to dismiss, and on Aug. 31, 2011 Judge Gonzalez granted dismissal without prejudice under Rules 12(b)(6) and 9(b) (Doc. 162). Applying In re BP Lubricants USA, Inc., 637 F.3d 1307 (Fed. Cir. 2011), Juniper Networks v. Shipley, 643 F.3d 1346 (Fed. Cir. 2011), and Pequignot v. Solo Cup, 608 F.3d 1356 (Fed. Cir. 2010), the court held that Troll Busters' licensor/licensee royalties-and-expiration inferential chain was speculative and that the "gigantic" inferential steps it asked the court to take could not supply the specific "who, what, when, where, and how" of the alleged deception; it gave plaintiff 30 days to amend. Plaintiff never did: it filed a notice of voluntary dismissal as to all defendants on Oct. 7, 2011 (Doc. 165), with the last defendant (Eurogentec) dismissed by order of Oct. 12, 2011 (Doc. 169). Note the metadata discrepancy: the case is reported as terminated Sept. 1, 2011, which appears to be the statistical closure after the Aug. 31 dismissal order, while the docket-aggregator termination date is Oct. 11–12, 2011. The case is notable on four axes: (1) it was a flagship example of the 2009–2011 false-marking boom that followed Forest Group's per-article damages holding — roughly 1,300 such suits were filed before BP Lubricants, per the NIU Law Review account — and of the biotech/life-sciences reagent industry as the next target after consumer goods; (2) it illustrates the BP Lubricants/Rule 9(b) pleading wall that killed most relator cases; (3) its timing is dispositive: the America Invents Act, signed Sept. 16, 2011, § 16, eliminated the § 292(b) qui tam mechanism, limited recovery to parties suffering "competitive injury," and excluded expired patents from the "unpatented article" definition, expressly applying "to all cases, without exception, that are pending on, or commenced on, or after" enactment — which is why a plaintiff with leave to amend instead walked away three weeks later (see Brooks v. Dunlop Mfg., No. 10-04341, 2011 WL 6140912 (N.D. Cal. Dec. 9, 2011), describing the same dynamic); and (4) it is not an IPR case — IPR did not exist until Sept. 16, 2012, the patents were expired, and no PTAB proceeding is associated with it. The parallel ecosystem worth noting for context is the earlier, real PCR patent war over these same Cetus/Roche patents (Hoffmann-La Roche v. Promega), which produced the '818 unenforceability judgment that animated Roche's Taq licensing program — the very program Troll Busters attacked as the marking vehicle.

Sourcing caveats: The docket entries (Docs. 84, 162, 165, 168–169) and Judge Gonzalez's Aug. 31, 2011 order are verified through Justia/PACER-derived copies. The full 22-patent list, accused-product tables, and Troll Busters' corporate self-description come from the FAC analysis and contemporaneous commentary rather than the complaint PDF itself, and the United States' intervenor status rests on an aggregator entry (UniCourt) that I could not confirm from a DOJ or court filing. I found no Law360, Reuters, or RPX coverage of this specific case in the sources reviewed, and no PTAB/IPR records, which is expected given the 2011 close and the expired status of the patents.

I'll research this case using web search to build a grounded chronology.

Good initial results. Let me dig into the docket chronology, the government's involvement, and any related proceedings.

Let me pull the full text of the key order (Doc. 162) and the docket report for precise dates and rulings.

Case roadmap: Troll Busters LLC v. Roche Diagnostics GmbH, No. 3:11-cv-00056-IEG-WVG (S.D. Cal.)

Bottom line: This was not an infringement action despite the PACER "Nature of Suit: Patent / § 1338" label. It was a qui tam false-marking action under 35 U.S.C. § 292(b), filed against 15 PCR/molecular-biology defendants over 22 expired patents (including US 4,889,818). It never reached claim construction, discovery, or trial. It ended in voluntary dismissal in October 2011, roughly three weeks after Judge Gonzalez dismissed the First Amended Complaint for failure to plead fraud with Rule 9(b) particularity.

---

1. Filing and initial pleadings

Context: the suit was one of the ~1,300 false-marking cases spawned by Forest Group, Inc. v. Bon Tool Co., 590 F.3d 1295 (Fed. Cir. 2009) (per-article penalty). A defense-side blog flagged the irony of an entity calling itself "Troll Busters" acting as a "marking troll" (falsepatentmarking.blogspot.com, 2011-01-18).

2. Pre-trial motions of substance — the coordinated motions to dismiss

• 2011-05-09 (approx.) — Defendants filed a coordinated set of Rule 12(b)(6) motions attacking the FAC for failure to plead intent to deceive with Rule 9(b) particularity: Docs. 90 (Cepheid), 91 (Roche Applied Sciences / Roche Molecular Systems), 92 (Roche Diagnostics GmbH), 94 (Eurogentec), 96 (Clontech), 102 (IDT), 103 (Gene Link), 105 (TriLink), 107 (Quanta), 111 (Qiagen — motion to dismiss, to quash service, or to transfer venue), 114 (EMD). Life Technologies joined the Roche motion rather than filing separately.
• 2011-05-27 — Plaintiff's oppositions filed, including Doc. 123 (opposition to the Roche motion) and Doc. 131 (opposition to Life's joinder). Troll Busters argued that its licensor/licensee allegations supplied the "objective indication" of knowledge required by In re BP Lubricants USA, Inc., 637 F.3d 1307 (Fed. Cir. 2011).
• 2011-08-12 — Hearing on all motions; Judge Gonzalez took them under submission (minute order Doc. 160; transcript Doc. 161, filed 2011-08-17).
• No motion to transfer was ever ruled on the merits — the Qiagen venue/service relief (Doc. 111) was disposed of as moot, "in part and … as moot with prejudice."
• There was no stay motion, no IPR stay (IPRs did not exist yet), and no summary-judgment practice.

3. The dispositive ruling — 2011-08-31 order (Doc. 162)

Judge Gonzalez granted all twelve motions to dismiss, without prejudice, with 30 days' leave to amend. Key holdings, relevant to every defendant including Roche and Life:

1. Legal framework: § 292 requires intent to deceive and "sounds in fraud"; therefore Rule 9(b) applies and the relator must plead "the specific who, what, when, where, and how." Juniper Networks v. Shipley, 643 F.3d 1346 (Fed. Cir. 2011); In re BP Lubricants, 637 F.3d 1307; Pequignot v. Solo Cup, 608 F.3d 1356 (Fed. Cir. 2010); Forest Group.
2. "Who" — satisfied. The court held the FAC adequately alleged the "who," noting the Federal Circuit does not require naming specific individuals.
3. "When" — insufficient. Although the FAC pled ongoing marking and listed each patent's expiration date, it gave no notice of when within the expired-patent window the marking occurred; a web search of unspecified date could not support "ongoing" marking.
4. "Where" — insufficient. All allegations were pleaded "on information and belief" and in the alternative ("either marked … or required customers to obtain licenses"). Critically, at the hearing plaintiff conceded it was unaware of any place where the expired patents were actually marked on or affixed to a product, and conceded that requiring customers to take licenses to expired patents does not violate § 292. The case therefore collapsed into a website-catalog-marking theory only.
5. "What" — "most troubling." Failure to identify with particularity which statements in which catalogs constituted the false marking.
6. Intent — speculative. The court rejected as "gigantic" inferential leaps the chain that Roche/Life were licensors, collected and stopped collecting royalties, notified licensees of expiration, and nonetheless required continued marking. "Large, sophisticated company" allegations were the very sort rejected in BP Lubricants; the FAC "contains no underlying facts" about the alleged post-expiration website edits; industry publications about 2005–2006 expirations could not establish intent as to patents expiring later.
7. Leave to amend granted, because Rule 9(b) dismissals should "ordinarily be without prejudice" (Vess v. Ciba-Geigy).

Note that the two "in part" rulings (Docs. 92 and 111) reflect partial grants tied to the Qiagen venue/service relief and one Roche entity; the balance of each was granted without prejudice on the Rule 9(b) ground.

4. Claim construction / discovery / trial

None of these phases occurred. No Markman order, no Clontech-style claim-scope analysis of the '818 patent (the "unpatented article" element was treated as satisfied by expiration), no scheduling order, no fact or expert discovery of record, no dispositive motion practice, no trial, no verdict, no JMOL/new-trial/fee motions. The Rule 9(b) dismissal was expressly designed to prevent "relators from using discovery as a fishing expedition" (Juniper, quoted in the order).

5. Final disposition

• No second amended complaint was filed within the 30-day window (which ran out around 2011-09-30). That date likely explains the "terminated 2011-09-01" flag in your metadata — it does not match the docket's formal closing entries, so treat it as a docket-administration artifact rather than the dismissal date.
• 2011-10-07 — Notice of Voluntary Dismissal (Doc. 165) as to all defendants other than Eurogentec.
• 2011-10-11 — Joint motion to dismiss Eurogentec (Doc. 168); an earlier notice as to Eurogentec (Doc. 166) was withdrawn (Doc. 167).
• 2011-10-12 — Order (Doc. 169) granting the joint motion and providing that, based on the Doc. 165 notice, "this case is dismissed in its entirety." (Patexia lists a termination date of 2011-10-11; the signed order is dated 10/12.)
• No appeal. A voluntary dismissal without prejudice is not appealable by the plaintiff, and there is no Federal Circuit docket for this case. Present posture: closed, no merits adjudication, no judgment, no injunction, no monetary award, and no publicly reported settlement.

6. Parallel PTAB / IPR proceedings

None. The asserted patents are expired PCR patents; the case terminated in October 2011, and the AIA's inter partes review provisions did not take effect until 2012-09-16. No IPR, PGR, CBM, or reexamination relating to the '818 patent appears connected to this litigation.

7. The legislative event that overshadowed the dismissal

On 2011-09-16 — sixteen days after the Rule 9(b) order and three weeks before the voluntary dismissal — the Leahy-Smith America Invents Act was signed. AIA § 16 eliminated the § 292(b) qui tam provision (penalties now recoverable only by the United States), replaced it with a competitive-injury damages remedy, and expressly excluded marking with an expired patent from liability, applicable "to all cases, without prejudice, pending on, or commenced on or after" enactment. That amendment retroactively stripped Troll Busters of its cause of action and any recovery, which is the practical explanation for the October dismissal without any attempt to amend. Related contemporaneous authority: FLFMC, LLC v. Wham-O, Inc., 444 F. App'x 447 (Fed. Cir. 2011) (AIA mooted a pending § 292(b) qui tam appeal); Brooks v. Dunlop Mfg. (N.D. Cal. 2011) (rejecting due-process/takings challenge to retroactive application).

---

Sourcing and caveats

• Well grounded: complaint date; FAC date and content (Doc. 84 ¶¶ 69, 95); the twelve MTD docket numbers and their Disposition; opposition dates (Docs. 123, 131); hearing 2011-08-12; the 2011-08-31 order's reasoning and quotations (full text at https://law.justia.com/cases/federal/district-courts/california/casdce/3:2011cv00056/[341819/162](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=341819-0162)/ and https://cases.justia.com/federal/district-courts/california/casdce/3:2011cv00056/[341819/162](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=341819-0162)/0.pdf); dismissal

I'll research this case and its docket to identify plaintiff's counsel.

Bottom line

Plaintiff Troll Busters LLC was represented by a Texas-centric plaintiffs' team (Dallas/Austin), not by San Diego local counsel of record that I could identify. The name appearing on essentially every plaintiff-side filing — including the voluntary dismissal that ended the case — is Karl A. Rupp (then of the Kendall Law Group, Dallas). A secondary aggregator (UniCourt) also lists Bradley E. Beckworth, Alan D. Albright, Heath Aaron Novosad, and Stephen B. Crain as plaintiff-side attorneys of record.

⚠️ Two threshold caveats before the table:

1. This was not a patent infringement case. Despite the docket's "Nature of Suit: Patent / 28 U.S.C. § 1338" label and the prompt's framing, this was a qui tam false-marking action under 35 U.S.C. § 292, brought by a self-described anti-troll entity, over 22 expired PCR patents (including US 4,889,818). There were no infringement claims. That matters for assessing counsel's role and experience.
2. Verification level is uneven. I confirmed Rupp as filer directly from docket entries; the other four names come from a third-party docket aggregator (UniCourt) whose list is explicitly truncated ("21 More Attorneys Available"), and I could not independently confirm firm affiliation as of 2011 for Albright, Novosad, or Crain from a primary filing. I flag each accordingly rather than guess.

Counsel of record for Plaintiff Troll Busters LLC

Local counsel: I found no San Diego-based local counsel of record in the materials available to me. If one existed, it does not appear in the aggregator list I could access, and S.D. Cal. did not then require local counsel as strictly as some districts.

Docket anchors for the plaintiff's filings

• Doc. 84 — First Amended Complaint (filed 2011-04-08), the operative pleading attacked in the dismissal motions.
• Doc. 123 — Plaintiff's Response in Opposition to the Roche Molecular Systems / Roche Diagnostics Corp. motion to dismiss.
• Doc. 131 (filed 05/27/2011) — Plaintiff's Opposition to Life Technologies Corp.'s joinder in the Roche motion.
• Doc. 162 (08/31/2011) — Judge Gonzalez's order granting the motions to dismiss without prejudice under Rule 9(b)/Juniper Networks/In re BP Lubricants, with 30 days leave to amend. The court noted that "both the content of Plaintiff's opposition papers and representation made by counsel at the hearing" suggested the defects were curable.
• Docs. 165–169 (Oct. 2011) — Plaintiff's notices of voluntary dismissal (Rupp signing) and the 10/12/2011 joint dismissal of Eurogentec North America, which closed the case in its entirety. Note: your case metadata lists termination as 09/01/2011, while the docket reflects the final all-defendant dismissal on 10/12/2011; 09/01/2011 appears to correspond to the dismissal-order deadline/administrative closure rather than the final judgment.

How to close the verification gaps

If you need certifiable counsel-of-record information (e.g., for a conflicts check or an exemplar brief), pull these from PACER (docket 3:11-cv-00056-IEG-WVG):

1. Doc. 1 (Complaint, 01/10/2011) and Doc. 84 (FAC) — the signature block will give the complete filing firm(s) and bar numbers, which is the authoritative answer.
2. Doc. 123 / 131 — opposition signature blocks typically list every attorney who worked the brief, including "of counsel."
3. The CM/ECF "Attorneys" report for the case, which resolves firm-of-record at the time of filing rather than a modern aggregated firm history.

I did not locate a Law360, Reuters Legal, or court-opinion source naming plaintiff's counsel beyond the above, and I have not attributed any attorney whose appearance I could not trace to a docket entry or filings index.

I'll research the docket and counsel appearances for this case.

Let me pull the full attorney list from docket mirrors and RECAP.

Bottom line

I can identify the defense-side attorney roster from the PACER-derived docket indexes, but I cannot verify firm affiliations or lead/local role designations from a primary source for most of them without pulling the caption blocks of the individual motions (Dkts. 90–114), which I was not able to retrieve in full. Below I separate what is documented from what is inference, and I flag the gaps explicitly rather than filling them in.

One threshold correction: despite the "patent infringement" nature-of-suit code (28 U.S.C. § 1338), this was not an infringement case — it was a qui tam false-marking action under 35 U.S.C. § 292, with the United States as a statutory real party in interest. That matters for counsel: appearances track defendant groups, not a single uniform defense team, and the U.S. appeared through its own counsel.

---

1. Documented defense appearances

The S.D. Cal. docket (No. 3:11-cv-00056-IEG-WVG) as mirrored by UniCourt/Patexia lists these attorneys on the defense side. Roles/firms are not stated in these indexes.

This list is incomplete. UniCourt shows "21 more attorneys available" and Patexia reports 38 defendant attorneys across 15 defendant entities (Roche Diagnostics GmbH, Roche Molecular Systems, Roche Diagnostics Corp./Roche Applied Science, Life Technologies, Eurogentec North America, Clontech Laboratories, Integrated DNA Technologies, Qiagen NV, Thermo Fisher Scientific, Quanta Biosciences, Gene Link, GenScript USA, EMD Chemicals, TriLink BioTechnologies, Cepheid). With 15 separately-represented defendants, there is no single "lead counsel" for the defense; each group filed its own Rule 12(b)(6)/9(b) motion.

Also noted in Dkt. 164: an attorney named MacFerrin was recorded as "not associated in case" — i.e., never properly appeared.

2. Plaintiff and intervenor counsel (for context)

• Troll Busters LLC: Karl A. Rupp; Bradley E. Beckworth; Alan D. Albright; Heath Aaron Novosad; Stephen B. Crain.
• United States (intervenor defendant/real party in interest): Thomas C. Stahl — consistent with a U.S. Department of Justice, Civil Division appearance, since § 292(b) gives the government a right to intervene and half of any fine.

3. Where the firm/role data actually lives

The caption blocks of these filings carry the full name/firm/address/SBN information and would let you (or me, on a follow-up) complete the table:

• Motions to dismiss: Dkts. 90, 91, 92, 94, 96, 102, 103, 105, 107, 111, 114 (all resolved by Dkt. 162, 08/31/2011, Judge Gonzalez).
• Opposition briefing: e.g., Dkt. 123 (opposition to Roche Molecular Systems / Roche Diagnostics Corp. motion), Dkt. 131 (opposition to Life Technologies' joinder).
• Withdrawal/substitution: Dkts. 163–164 (Life Technologies).
• Termination: Dkt. 165 (Notice of Voluntary Dismissal, 10/07/2011); Dkt. 169 (order dismissing Eurogentec, 10/12/2011).

Opinion citation: Troll Busters, LLC v. Roche Diagnostics GMBH, No. 11cv56-IEG (WVG), 2011 WL 3876020 (S.D. Cal. Aug. 31, 2011) (dismissing FAC without prejudice under Rules 12(b)(6) and 9(b)); see also Justia docket, https://dockets.justia.com/docket/california/casdce/3:2011cv00056/341819.

4. What I am not asserting

I have not fabricated firm names, office locations, or "lead counsel" labels. For every attorney in the table above other than the two Life Technologies appearances (which are tied to specific docket entries), I could not, in this pass, tie the name to a firm or an office location from PACER, a firm website, a court opinion, Law360, or Reuters Legal. Any firm attribution you see elsewhere for these individuals should be checked against the Dkt. 90–114 caption blocks before being relied on.

If you want, the next step is to pull the PDF headers for Dkts. 90–114 and 123/131, which would convert most of the "not verified" cells into sourced entries in one pass.